双极性抑郁症的胺:一个更新的系统性审查
Farhan Fancy1,2, Sipan Haikazian1,2, Danica E Johnson1,2
1Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Therapeutic advances in psychopharmacology
|September 29, 2023
概括
静脉注射胺对双极性抑郁症 (BD) 治疗有前途,近一半的患者反应良好. 虽然通常是安全的,但有些人经历了躁狂症状,表明需要进一步研究.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 亚麻醉式胺显示在单极性抑郁症中具有治疗潜力.
- 胺对双极性抑郁症 (BD) 的疗效在很大程度上仍未被描述.
研究的目的:
- 系统地审查凯胺在治疗双极性抑郁症 (BD) 的成年人中的疗效,安全性和耐受性.
主要方法:
- 随机对照试验,开放试验和回顾性图表分析的系统审查.
- 在PubMed和Embase数据库中搜索到2023年3月13日之前发表的研究.
- 包括8项研究,共有235名成人参与者患有BD.
主要成果:
- 静脉注射 (IV) 胺 (0.5-0.75 mg/kg) 或胺 (28-84 mg) 用作辅助治疗.
- 48%的凯胺接受者在抑郁症严重程度下降了50%,而安慰剂的比例为5%.
- 与临床试验 (63%) 相比,现实世界的研究显示反应率较低 (30%).
- 胺一般耐受良好,有2%的人经历过低躁狂/躁狂症状,有些人报告分裂性影响.
结论:
- 初步证据表明,IV胺在治疗双极性抑郁症 (BD) 中是安全有效的.
- 需要进一步的研究,特别是对反复输注和维护输注的随机对照试验.
相关概念视频
01:30Electroconvulsive Therapy
59
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
59
01:24Mania and Antimanic Drugs: Overview
215
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
215
01:28Drug Therapy
60
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
60
01:30Bipolar Disorder
78
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
78
01:26Psychosis: Goals of Pharmacotherapy
158
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
158
01:23Antidepressant Drugs: MAOIs and Other Agents
266
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
266